CTOs on the Move

Lyra Therapeutics

www.Lyratx.com

 
We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.Lyratx.com
  • 480, Arsenal Street
    Watertown, MA USA 02472
  • Phone: 617.393.4600

Executives

Name Title Contact Details

Similar Companies

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals Corporation is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EUSA Pharma

EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are

Lupin

Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

NxStage Medical

NxStage System One dialysis machines offer the comfort and flexibility of hemodialysis at home. Discover how our products can improve your quality of life.

Flowr Corporation

The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.